Caris Life Sciences (CAI) Operating Expenses (2024 - 2026)

Caris Life Sciences' Operating Expenses history runs 3 years deep, the most recent figure standing at $210.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 17.9% year-over-year to $210.9 million; the TTM figure through Mar 2026 stood at $798.9 million (up 18.3% YoY), while the FY2025 annual figure was $766.9 million, up 14.57% from the prior year.
• Operating Expenses was $210.9 million for Q1 2026 at Caris Life Sciences, up from $204.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $210.9 million in Q1 2026 to a low of $162.5 million in Q3 2024.
• Historically, Operating Expenses has averaged $184.3 million across 3 years, with a median of $181.5 million in 2025.
• Biggest YoY gain for Operating Expenses was 22.47% in 2025; the steepest drop was 13.37% in 2025.
• A 3-year view of Operating Expenses shows it stood at $167.0 million in 2024, then grew by 22.47% to $204.5 million in 2025, then increased by 3.14% to $210.9 million in 2026.
• The last three Operating Expenses figures came in at $210.9 million (Q1 2026), $204.5 million (Q4 2025), and $184.2 million (Q3 2025), per Business Quant data.